Andrea Califano, Dr

Dr. Califano is a pioneer in the field of systems biology. A physicist by training, Dr. Califano has taken innovative, systematic approaches to identify the molecular factors that lead to cancer progression and to the emergence of drug resistance at the single-cell level. Directing the conversation about cancer research away from focusing solely on gene mutations, Dr. Califano examines the complex and tumor-specific molecular interaction networks that determine cancer cell behavior. Using information theoretic approaches, analysis of these networks can precisely pinpoint master regulator proteins that are mechanistically responsible for supporting tumorigenesis and for implementing tumor cell homeostasis. Dr. Califano and his lab have shown that master regulators represent critical drivers and tumor dependencies, despite the fact that they are rarely mutated or differentially expressed, thus establishing them as a bona fide new class of therapeutic targets.

The Califano Systems Biology Lab combines computational and experimental methodologies to reconstruct the regulatory and signaling logic of human cells in genome-wide fashion. In addition, his lab has developed methods for the systematic discovery of small molecule compounds and combinations that can inactivate master regulator proteins in cancer, thus providing novel therapeutic hypotheses that can be validated pre-clinically and clinically. Indeed, several of his findings have been translated into clinical studies, including an innovative N-of-1 study at Columbia in which master regulators are identified and pharmacologically targeted on an individual patient basis in several aggressive malignancies, thus getting a step closer to deliver on the promise of a truly mechanistic implementation of precision medicine. Dr. Califano's master regulator analyses have led to several discoveries that are being tested in the clinics, including the drug entinostat in a subset of metastatic neuroendocrine tumor patients, the use of combination therapy in HER2+ and inflammatory breast cancer, and additional phase 2 clinical trials in patients with recurrent pancreatic ductal carcinoma and metastatic prostate cancer. His research has been funded by the National Cancer Institute, Lustgarten Foundation, Falconwood Foundation, Hyundai Hope on Wheels, the NET Research Foundation, and the Prostate Cancer Foundation.